OncXerna Therapeutics Reports P-II Trial Results of Bavituximab + Pembrolizumab and New Xerna TME Panel Biomarker Data for Advanced Hepatocellular Carcinoma


The P-II trial evaluating bavituximab + pembrolizumab in 28 patients at the University of Texas Southwestern Harold C. SCCC
The results showed that patients treated with bavituximab + pembrolizumab achieved a 62.5% response rate in biomarker positive subgroup & the combination therapy was well tolerated with no new safety signals. The results were presented at ASCO GI 2023
The results reinforce the potential of the Xerna TME panel to identify patients who are more likely to benefit from targeted & immune therapies across multiple malignancies. The tumor biopsy analysis revealed that the response rate was increased in Xerna TME biomarker-positive patients while biomarker-negative patients experienced higher rates of progressive disease

Ref: OncXerna | Image: OncXerna

Related News:- Ipsen Presents P-III Trial (NAPOLI 3) Results of Onivyde for Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI 2023